Abstract:Background: A person’s rate of aging has important implications for his/her risk of death and disease, thus, quantifying aging using observable characteristics has important applications for clinical, basic, and observational research. We aimed to validate a novel aging measure, “Phenotypic Age”, constructed based on routine clinical chemistry measures, by assessing its applicability for differentiating risk for morbidity and mortality in both healthy and unhealthy populations of various ages. Methods: A nationally representative US sample, NHANES III, was used to derive “Phenotypic Age” based on a linear combination of chronological age and nine multi-system clinical chemistry measures, selected via cox proportional elastic net. Mortality predictions were validated using an independent sample (NHANES IV), consisting of 11,432 participants, for whom we observed a total of 871 deaths, ascertained over 12.6 year of follow-up. Proportional hazard models and ROC curves were used to evaluate predictions. Results: Phenotypic Age was significantly associated with all-cause mortality and cause-specific mortality. These results were robust to age and sex stratification, and remained even when excluding short-term mortality. Similarly, Phenotypic Age was associated with mortality among seemingly “healthy” participants—defined as those who were disease-free and had normal BMI at baseline—as well as the oldest-old (aged 85+)—a group with high disease burden. Conclusions: Phenotypic Age is a reliable predictor of all-cause and cause-specific mortality in multiple subgroups of the population. Risk stratification by this composite measure is far superior to that of the individual measures that go into it, as well as traditional measures of health. It is able to differentiate individuals who appear healthy, who may have otherwise been missed using traditional health assessments. Further, it can differentiate risk among persons with shared disease burden. Overall, this easily measured metric may be useful in the clinical setting and facilitate secondary and tertiary prevention strategies.

Molecular and phenotypic biomarkers of aging

Molecular and phenotypic biomarkers of aging [version 1; referees: 3 approved]

Phenotypic Age: a novel signature of mortality and morbidity risk

An evaluation of aging measures: from biomarkers to clocks

EPIGENETIC PROFILES OF BIOLOGICAL AGING HALLMARKS

Development and Validation of Two Composite Aging Measures Using Clinical Biomarkers in the Chinese Population

Epigenomic, Transcriptome And Image-Based Biomarkers Of Aging

GENETIC PREDISPOSITION TO ACCELERATED BIOLOGICAL AGES PREDICTED BY BIOCHEMICAL MARKERS

Biomarkers of Aging and Relevant Evaluation Techniques: A Comprehensive Review

Molecular and physiological manifestations and measurement of aging in humans

Identifying biological markers and sociodemographic factors that influence the gap between phenotypic and chronological ages

An epigenetic biomarker of aging for lifespan and healthspan

Comprehensive Insights from Molecular Targets and Biomarkers to Biological Clocks

Aging Biomarkers and Novel Targets for Anti-Aging Interventions.

Progress in the study of aging marker criteria in human populations

Models for Evaluation of Biological Age Based on Multi-omics

Validation of biomarkers of aging

Biomarkers of aging in real life: three questions on aging and the comprehensive geriatric assessment

The Aging Biomarker Consortium represents a new era for aging research in China

Biomarkers of Cellular Senescence and Aging: Current State-of-the-Art, Challenges and Future Perspectives

Phenotype correlations reveal the relationships of physiological systems underlying human ageing